Assessment of Eloquent Function in Brain Tumor Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Purpose of the study:
AIM 1 Prospectively collect pre-operative (fMRI, DTI, MEG) and intra-operative mapping data in patients with intra-axial brain tumors to assess how well each modality predicts the location of eloquent brain function. In addition, each modality will be compared with the other.
AIM 2 Assess reorganization of eloquent brain function and plasticity in patients with intra-axial brain tumors. This will be accomplished by prospectively collecting post-operative mapping studies and neuropsychological tests to compare them to prior mapping studies as stated above.
| Condition |
|---|
|
Primary Brain Tumor Metastatic Brain Tumor |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Assessment of Reorganization and Plasticity of Eloquent Function in Patients With Brain Tumors |
- Eloquent function [ Time Frame: 1 year ] [ Designated as safety issue: No ]The location of the eloquent function of interest (motor, sensory, speech) will be assessed pre-operatively and intra-operatively. These will be compared. Then, at 2 and 6 months post-operatively, repeat non-invasive mapping studies will be performed to compare to the subjects' prior studies. This will allow for assessment of reorganization and plasticity of function.
| Estimated Enrollment: | 10 |
| Study Start Date: | January 2012 |
| Estimated Study Completion Date: | February 2015 |
| Estimated Primary Completion Date: | February 2014 (Final data collection date for primary outcome measure) |
Any patient with a primary or metastatic brain tumor in or near an eloquent area would be eligible for participation in the study assuming no contraindications to any of the studies or operative procedure.
Pre-operative:
Evaluation will include clinical evaluation, neuropsychological testing, MRI brain with and without contrast, fMRI, DTI tractograms, and MEG studies as well as standard pre-operative work-up.
Intra-operative:
All non-invasive pre-operative mapping data will be incorporated into the operative procedure with the imaging tools that we routinely use during neurosurgical procedures. Patients will have awake mapping performed. Our usual standards of care will be followed during craniotomy, mapping, and tumor resection or biopsy.
Post-operative:
Patients will have routine post-operative care and assessment consisting of clinical examinations and imaging obtained within 24 hours post resection. They will have routine follow-up outpatient appointments after surgery which will include neurologic assessment and follow-up imaging (MRI with and without contrast) for their tumors as appropriate. The experimental portion of the protocol is incorporating repeat neuropsychological testing and mapping studies (fMRI, DTI, MEG) studies at 2 and 6 months post-surgery into their routine follow-up.
Eligibility| Ages Eligible for Study: | 19 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patient with a brain tumor in or near an area of eloquent brain function (speech, motor, sensory).
Inclusion Criteria:
- Patients 19 years and older.
- Brain tumor in or near eloquent brain regions that is appropriate for attempted resection.
- Appropriate body habitus and mental status/capacity to participate with non-invasive or invasive mapping.
- Benign or malignant intra-axial brain tumor.
- Primary or metastatic intra-axial brain tumor.
Exclusion Criteria:
- Any patient with a contraindication to MRI (i.e. implanted devices)
- Inappropriate body habitus or mental status/capacity to participate with non-invasive or invasive mapping in a safe and reliable manner.
- Patient declines to participate.
- Patient that does not have the capacity to understand the study or consent for themselves.
- Neurologic status which precludes them from testing (poor function- not testable).
- Positive pregnancy test in females.
- Any patient with end stage renal disease or severe renal dysfunction.
Contacts and Locations| Contact: Michele Aizenberg, MD | 402-559-9614 | maizenberg@unmc.edu |
| Contact: Vicki Wolpa, RN | 402-559-9602 | vwolpa@nebraskamed.com |
| United States, Nebraska | |
| University of Nebraska Medical Center | Recruiting |
| Omaha, Nebraska, United States, 68198 | |
| Contact: Michele Aizenberg, MD 402-559-9614 maizenberg@unmc.edu | |
| Contact: Vicki Wolpa, RN 402-559-9602 vwolpa@nebraskamed.com | |
| Principal Investigator: Michele Aizenberg, MD | |
| Principal Investigator: | Michele Aizenberg, MD | University of Nebraska |
More Information
No publications provided
| Responsible Party: | University of Nebraska |
| ClinicalTrials.gov Identifier: | NCT01535430 History of Changes |
| Other Study ID Numbers: | 671-11-FB |
| Study First Received: | February 8, 2012 |
| Last Updated: | February 14, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Nebraska:
|
brain mapping brain tumor |
Additional relevant MeSH terms:
|
Brain Neoplasms Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site |
Neoplasms Brain Diseases Central Nervous System Diseases Nervous System Diseases |
ClinicalTrials.gov processed this record on May 22, 2013